November 21, 2017 – In a complaint filed November 20, 2017, the University of Texas and licensee TissueGen allege infringement of two patents directed to biodegradable drug-releasing fibers by several of Boston Scientific’s drug-eluting stents.
The case is captioned Board of Regents of The University of Texas System v. Boston Scientific Corp., case number 17-cv-01103, in the Western District of Texas. U.S. Patent Nos. 6,596,296 and 7,033,603, respectively entitled Drug Releasing Biodegradable Fiber Implant and Drug Releasing Biodegradable Fiber for Delivery of Therapeutics, have been asserted.
By: Sean C. McDonagh